E-vita OPEN NEO治疗急慢性主动脉病变:NEOS研究首次中期结果
这项多中心观察性研究在12个中心纳入100例患者,评估E-vita OPEN NEO支架象鼻系统治疗升主动脉、主动脉弓和降胸主动脉急慢性动脉瘤或夹层的安全性和临床表现,30天死亡率为5.1%,估计6个月生存率为91.6%。
要点
- 100例患者中99例接受手术,包括急性/亚急性A型夹层37例、慢性A型夹层33例和胸主动脉瘤29例。
- 24小时器械技术成功率为97.0%,出院时新发致残性卒中为4.4%。
- 30天死亡率为5.1%,估计6个月生存率为91.6%(标准差2.9)。
核心结论
- 使用E-vita OPEN NEO行全弓置换在急性和慢性情况下均可获得优异结果,表明该器械可安全使用,包括急性A型主动脉夹层。
研究设计与样本
- 这项观察性研究在12个中心(欧洲和亚洲)于2020年12月至2022年3月期间纳入患者,所有患者均使用E-vita OPEN NEO支架象鼻系统行冰冻象鼻手术。
主要发现
- 共纳入100例患者(男性66.7%;平均年龄57.7岁),99例接受手术:急性或亚急性A型主动脉夹层37例,慢性A型主动脉夹层33例,胸主动脉瘤29例,1例未手术。
- 24小时器械技术成功率为97.0%。
- 出院时新发致残性卒中为4.4%,新发截瘫为2.2%,新发轻瘫为2.2%,需要永久(>90天)透析或血液滤过的肾衰竭为3.3%。
- 出院至3-6个月随访期间,无患者出现新发致残性卒中、新发截瘫或新发轻瘫。
- 30天死亡率为5.1%,估计6个月生存率为91.6%(标准差2.9)。
临床怎么用
- 原文未报告临床实践建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this multicentre study was to demonstrate the safety and clinical performance of E-vita OPEN NEO Stent Graft System (Artivion, Inc.) in the treatment of aneurysm or dissection, both acute and chronic, in the ascending aorta, aortic arch and descending thoracic aorta. METHODS: In this observational study of 12 centres performed in Europe and in Asia patients were enrolled between December 2020 and March 2022. All patients underwent frozen elephant trunk using E-vita OPEN NEO Stent Graft System. Primary end point was the rate of all-cause mortality at 30 days and secondary end points included further clinical and safety data are reported up to 3-6 months postoperatively. RESULTS: A total of 100 patients (66.7% male; mean age, 57.7 years) were enrolled at 12 sites. A total of 99 patients underwent surgery using the E-vita OPEN NEO for acute or subacute type A aortic dissection (n = 37), chronic type A aortic dissection (n = 33) or thoracic aortic aneurysm (n = 29), while 1 patient did not undergo surgery. Device technical success at 24 h was achieved in 97.0%. At discharge, new disabling stroke occurred in 4.4%, while new paraplegia and new paraparesis was reported in 2.2% and 2.2%, respectively. Renal failure requiring permanent (>90 days) dialysis or hemofiltration at discharge was observed in 3.3% of patients. Between discharge and the 3-6 months visit, no patients experienced new disabling stroke, new paraplegia or new paraparesis. The 30-day mortality was 5.1% and the estimated 6-month survival rate was 91.6% (standard deviation: 2.9). CONCLUSIONS: Total arch replacement with the E-vita OPEN NEO can be performed with excellent results in both the acute and chronic setting. This indicates that E-vita OPEN NEO can be used safely, including in the setting of acute type A aortic dissection.
引用
- Tsagakis K, Kempfert J, Zierer A, et al. E-vita OPEN NEO in the treatment of acute or chronic aortic pathologies: first interim results of the NEOS study. Eur J Cardiothorac Surg. 2024. PMID: 38830042. doi:10.1093/ejcts/ezae206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。